DE60117743D1 - Screeningverfahren für Modulatoren von Integrinen - Google Patents

Screeningverfahren für Modulatoren von Integrinen

Info

Publication number
DE60117743D1
DE60117743D1 DE60117743T DE60117743T DE60117743D1 DE 60117743 D1 DE60117743 D1 DE 60117743D1 DE 60117743 T DE60117743 T DE 60117743T DE 60117743 T DE60117743 T DE 60117743T DE 60117743 D1 DE60117743 D1 DE 60117743D1
Authority
DE
Germany
Prior art keywords
integrins
modulators
screening method
methods
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60117743T
Other languages
English (en)
Other versions
DE60117743T2 (de
Inventor
Jacques Hamon
Emmanuel Normant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE60117743D1 publication Critical patent/DE60117743D1/de
Application granted granted Critical
Publication of DE60117743T2 publication Critical patent/DE60117743T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Optical Communication System (AREA)
  • Peptides Or Proteins (AREA)
DE60117743T 2001-11-05 2001-11-05 Screeningverfahren für Modulatoren von Integrinen Expired - Fee Related DE60117743T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01402843A EP1308726B1 (de) 2001-11-05 2001-11-05 Screeningverfahren für Modulatoren von Integrinen

Publications (2)

Publication Number Publication Date
DE60117743D1 true DE60117743D1 (de) 2006-05-04
DE60117743T2 DE60117743T2 (de) 2006-10-12

Family

ID=8182955

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117743T Expired - Fee Related DE60117743T2 (de) 2001-11-05 2001-11-05 Screeningverfahren für Modulatoren von Integrinen

Country Status (4)

Country Link
EP (1) EP1308726B1 (de)
AT (1) ATE319997T1 (de)
DE (1) DE60117743T2 (de)
ES (1) ES2257388T3 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687637A4 (de) * 2003-11-29 2007-09-05 Proteogen Inc Screening-verfahren mit hohem durchsatz für einen integrin-antagonisten und durch screening damit erhaltenes neues peptid
WO2007007151A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
US20130040845A1 (en) * 2010-02-16 2013-02-14 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
DE102017114537A1 (de) * 2017-06-29 2019-01-03 Endress+Hauser Conducta Gmbh+Co. Kg Sensormembran, Sensorkappe und optischer Sensor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837478A (en) * 1993-12-23 1998-11-17 Icos Corporation Method of identifying modulators of binding between and VCAM-1
PL323998A1 (en) * 1996-04-15 1998-04-27 Icos Corp Cytoplasmatic modulator for regulating/signalling integrins
DK1078006T3 (da) * 1998-05-13 2009-06-02 Genentech Inc Diagnose og behandling af leverlidelser

Also Published As

Publication number Publication date
ES2257388T3 (es) 2006-08-01
DE60117743T2 (de) 2006-10-12
ATE319997T1 (de) 2006-03-15
EP1308726A1 (de) 2003-05-07
EP1308726B1 (de) 2006-03-08

Similar Documents

Publication Publication Date Title
DE69527987T2 (de) Formulierungen und verfahren zur reduzierung von hautreizung
ATE251141T1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE512233T1 (de) Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
DE69434313D1 (de) Superoxiddismutase memetika
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
DE69711395D1 (de) Verfahren zur herstellung von cyclohexen-carboxylatderivate
ATE490758T1 (de) Färbezusammensetzung enthaltend einen bestimmten hydrophoben farbstoff und eine säure
DE60207514D1 (de) Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten
DE60320343D1 (de) Verwendung eines besonderen organischen Salzes zum Waschen und/oder Konditionieren von Keratinfasern, Verwendung eines besonderen organischen Salzes als Konditionierungsmittel für diese Fasern und ein Verfahren zur kosmetischen Behandlung
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
PT1017659E (pt) Tetra-hidronaftalenos substituidos e compostos analogos
ATE234812T1 (de) Integrin antagonisten
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
DE602004031458D1 (de) Verfahren zur erhöhung der refinerproduktionsrate und/oder verringerung der spezifischen energie des aufschliessens von holz
ES2173850T3 (es) Composicion cosmetica y su utilizacion como mascarilla de limpieza de la piel.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE60117743D1 (de) Screeningverfahren für Modulatoren von Integrinen
DE59010919D1 (de) N- und O-substituierte Aminophenolderivate, Zwischenprodukte zu deren Herstellung, deren Verwendung als Hydrolasesubstrate, ein entsprechendes Bestimmungsverfahren und hierfür geeignetes diagnostisches Mittel
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
ATE263373T1 (de) Verfahren und zusammensetzungen zum screenen von modulatoren von sphingosinkinasen
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee